Azasite Related Published Studies
Well-designed clinical trials related to Azasite (Azithromycin Ophthalmic)
Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. [2011.01]
Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. [2010.11]
[Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis] [2010.04]
Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients. [2010.03]
Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions. [2009.11]
Randomized trial of high dose azithromycin compared to standard dosing for children with severe trachoma in Tanzania. [2009.05]
Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. [2008.11]
Microbiological efficacy of 3-day treatment with azithromycin 1.5% eye-drops for purulent bacterial conjunctivitis. [2008.11]
Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial. [2008.06]
Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers. [2008.01]
Azithromycin prevents recurrence of severe trichiasis following trichiasis surgery: STAR trial. [2007.09]
Phase 3 Safety Comparisons for 1.0% Azithromycin in Polymeric Mucoadhesive Eye Drops versus 0.3% Tobramycin Eye Drops for Bacterial Conjunctivitis. [2007.08]
A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis. [2007.06]
Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial. [2007.05]
3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. [2007.04]
Single-dose azithromycin prevents trichiasis recurrence following surgery: randomized trial in Ethiopia. [2006.03]
A randomised controlled trial of azithromycin following surgery for trachomatous trichiasis in the Gambia. [2005.10]
Azithromycin vs doxycycline in the treatment of inclusion conjunctivitis. [2003.04]
The efficacy of azithromycin in the treatment of acute infraorbital space infection. [2003.03]
Operational comparison of single-dose azithromycin and topical tetracycline for trachoma. [2000.12]
Three-day course of oral azithromycin vs topical oxytetracycline/polymyxin in treatment of active endemic trachoma. [2000.07]
Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area. [1999.12]
A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. [1997.03]
Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. [1996.05]
Effects of azithromycin on malariometric indices in The Gambia. [1995.09.30]
Randomised controlled trial of single-dose azithromycin in treatment of trachoma. [1993.08.21]
Well-designed clinical trials possibly related to Azasite (Azithromycin Ophthalmic)
Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitudinal controlled study of patients undergoing intravitreal injections. [2011.09]
Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections. [2011.07]
Impact of Trichiasis surgery on physical functioning in Ethiopian patients: STAR trial. [2011.05]
Rates and risk factors for unfavorable outcomes 6 weeks after trichiasis surgery. [2011.04.25]
Trichiasis surgery in The Gambia: a 4-year prospective study. [2010.10]
Effect of trichiasis surgery on visual acuity outcomes in Ethiopia. [2009.11]
Surgery for Trichiasis, Antibiotics to prevent Recurrence (STAR) Clinical Trial methodology. [2005.08]
Other research related to Azasite (Azithromycin Ophthalmic)
Evaluation of single-dose azithromycin versus standard azithromycin/doxycycline
treatment and clinical assessment of regression course in patients with adult
inclusion conjunctivitis. [2013]
Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening
toxoplasmic retinochoroiditis: a pilot study. [2012]
Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous
conjunctivitis. [2012]
Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the
treatment of contact lens-related dry eye. [2012]
Toxicity comparison of intraocular azithromycin with and without a bioadhesive delivery system in rabbit eyes. [2011.11.09]
Effect of topical azithromycin on corneal innate immune responses. [2011.04.19]
Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis. [2011.03]
[Combined pharmacological-surgical treatment in exudative age-related macular degeneration]. [2011]
AzaSite(R) inhibits Staphylococcus aureus and coagulase-negative Staphylococcus biofilm formation in vitro. [2010.12]
Elimination of active trachoma after two topical mass treatments with azithromycin 1.5% eye drops. [2010.11.23]
Efficacy and safety of short-duration topical treatment with azithromycin oil-based eyedrops in an experimental model of corneal refractive surgery. [2010.11]
Mass treatment with azithromycin for trachoma control: participation clusters in households. [2010.10.05]
An anterior chamber toxicity study evaluating Besivance, AzaSite, and Ciprofloxacin. [2010.10]
New method for ophthalmic delivery of azithromycin by poloxamer/carbopol-based in situ gelling system. [2010.09]
Pharmacokinetics of Azithromycin and Moxifloxacin in Human Conjunctiva and Aqueous Humor During and After the Approved Dosing Regimens. [2010.08.31]
Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. [2010.08]
Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations. [2010.07]
Effect of oral azithromycin in the treatment of chlamydial conjunctivitis. [2010.06]
Effectiveness, tolerability and safety of azithromycin 1% in DuraSite for acute bacterial conjunctivitis. [2010.05.13]
Rapid, sensitive and selective liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of topically applied azithromycin in rabbit conjunctiva tissues. [2010.05.01]
Mass treatment of trachoma with azithromycin 1.5% eye drops in the Republic of Cameroon: feasibility, tolerance and effectiveness. [2010.02]
[Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on
clinical signs of purulent bacterial conjunctivitis]. [Article in French] [2010]
Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. [2009.10]
Azithromycin reduces ocular infection during congenital transmission of toxoplasmosis in the Calomys callosus model. [2009.08]
Trimethoprim/Sulfamethoxazole and azithromycin combination therapy for ocular toxoplasmosis. [2009.07]
Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma. [2009.07]
Lipid emulsions as a potential delivery system for ocular use of azithromycin. [2009.07]
Ocular pharmacokinetics of AzaSite Xtra-2% azithromycin formulated in a DuraSite delivery system. [2009.06]
Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. [2009.05]
Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin. [2009.04]
[Evaluation of effectiveness and tolerance of treatment with azithromycin 1.5% eye drops in bacterial conjunctivitis] [2009]
Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. [2008.09]
Use of azithromycin ophthalmic solution in the treatment of chronic mixed anterior blepharitis. [2008.06]
Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits. [2008.02]
An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite. [2007.12]
Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis. [2007.09]
Trachoma control using the who adopted "safe with azithromycin". [2007.03]
Longitudinal evaluation of three azithromycin distribution strategies for treatment of trachoma in a sub-Saharan African country, Mali. [2007.01]
Chlamydial positivity of nasal discharge at baseline is associated with ocular chlamydial positivity 2 months following azithromycin treatment. [2006.11]
Impact of oral azithromycin on recurrence of trachomatous trichiasis in Nepal over 1 year. [2006.08]
Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis. [2005.11]
Effects of dehydration on corneal tissue absorption of topical azithromycin in rabbits. [2005.10]
Microbiological assay for the determination of azithromycin in ophthalmic solutions. [2005.06]
Mass treatment with single-dose azithromycin for trachoma. [2004.11.04]
Corneal pharmacokinetics of topically applied azithromycin and clarithromycin. [2004.10]
Other possibly related research studies
Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. [2008.06]
The impact of community level treatment and preventative interventions on trachoma prevalence in rural Ethiopia. [2008.06]
Morbidity and mortality of mucocutaneous diseases in the pediatric population at a tertiary care center. [2007.11]
Acute choroidal ischemia associated with toxoplasmic retinochoroiditis. [2007.09]
Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. [2007.04]
[Chlamydial diseases of the eye. A short overview] [2007.01]
Bilateral acute anterior uveitis as a presenting symptom of Mycoplasma pneumoniae infection. [2006.10]
Can chlamydial conjunctivitis result from direct ejaculation into the eye? [2006.09]
[Stage-oriented treatment of Lyme borreliosis] [2006.06.22]
Interventions for trachoma trichiasis. [2006.07.19]
Mycobacterium chelonae keratitis after laser-assisted subepithelial keratectomy. [2006.06]
Spatial clustering of ocular chlamydial infection over time following treatment, among households in a village in Tanzania. [2006.01]
Tuberculosis. [2005.07]
Neonatal chlamydial infections: prevention and treatment. [2005]
Antibiotics for trachoma. [2005.04.18]
An index of community ocular Chlamydia trachomatis load for control of trachoma. [2005.03]
The effect of antibiotic treatment on active trachoma and ocular Chlamydia trachomatis infection. [2003.08]
Prevalence of trachoma in chronic conjunctivitis, Birjand, Islamic Republic of Iran. [2002.03]
Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. [2004.08.11]
Ophthalmomyiasis caused by the sheep bot fly Oestrus ovis in northern Iraq. [2004.08]
Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas? [2003.05.15]
Antibiotic dosage in trachoma control programs: height as a surrogate for weight in children. [2003.04]
Current trachoma treatment methodologies: focus on advancements in drug therapy. [2002]
|
